Results 31 to 40 of about 22,249,811 (294)

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas [PDF]

Blood, 2018
Programmed cell death protein 1 (PD-1) blockade targeting the PD-1 immune checkpoint has demonstrated unprecedented clinical efficacy in the treatment of advanced cancers including hematologic malignancies. This article reviews the landscape of PD-1/programmed death-ligand 1 (PD-L1) expression and current PD-1 blockade immunotherapy trials in B-cell ...
Xu-Monette, Zijun Y, Zhou, Jianfeng, Young, Ken H   +2 more
openaire   +2 more sources

The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology. [PDF]

, 2012
The balance between pro-inflammatory and regulatory immune responses in determining optimal T cell activation is vital for the successful resolution of microbial infections.
Couper, Kevin N, Claser, C, Riley, Eleanor M, Julius Clemence R Hafalla, Eleanor M Riley, Kevin N Couper, de Souza, J Brian, de Souza, J. Brian, Claser Carla, Renia L., Kevin N. Couper (25399), Grau, GE, Hafalla Julius Clemence R., Laurent Renia (63769), Couper, KN, Hafalla, Julius Clemence R, Grau G.E., Couper Kevin N., Grau, Georges Emile, de Souza, JB, Riley Eleanor M., J. Brian de Souza (25406), Claser C., Renia Laurent, Riley E.M., Hafalla J.C.R., Julius Clemence R. Hafalla (185909), de Souza J.B., de Souza J. Brian, Hafalla, JC, Riley, Eleanor M., Couper K.N., Renia, Laurent, Carla Claser, Georges Emile Grau, Carla Claser (185910), Couper, Kevin N., Georges Emile Grau (185911), Renia, L, Riley, EM, J Brian de Souza, Eleanor M. Riley (25407), Grau Georges Emile, Laurent Renia, Claser, Carla   +44 more
core   +1 more source

DataSheet_1_A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer.docx

, 2023
BackgroundHarnessing the anti-tumor immune system response by targeting the program cell death protein (PD-1) and program cell death ligand protein (PD-L1) axis has been a major breakthrough in non-small cell lung cancer (NSCLC) therapy.
Alfonso Calvo (487616), Jon Ander Simón (14501795), Alejandro Francisco-Cruz (17057562), Sergio Sandiego (17057568), Anna Vilalta-Lacarra (15248114), Inés López (2677498), Ander Puyalto (17057553), Daniel Ajona (709873), Iván Peñuelas (364321), María Rodríguez-Remírez (4319509), María Collantes (364320), Fabiola Iribarren (17057556), Jose Luis Solórzano (17057565), Ignacio Gil-Bazo (3505016), Marga Ecay (17057559)   +14 more
core   +1 more source

Liver immune-related adverse effects of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: A propensity score matched study with competing risk analyses [PDF]

, 2022
Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors, major classes of immune checkpoint inhibitors, are increasingly prescribed for different cancers.
Wai, A K C, Ng, K, Zhang, Q, Yoo, J W, Liu, T, Tse, G, Zhou, J, Dee, E C, Chau, Y-L A, Lee, S   +9 more
core   +1 more source

A dangerous mixture

Italian Journal of Medicine, 2014
A 59-year old woman was admitted for fatigue and arm paresthesias with Trousseau sign. Her medical history included thyroidectomy and hypercholesterolemia recently treated with simvastatin.
Anna Piva, Alessio Filippi, Natalino Simioni   +2 more
doaj   +1 more source

Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors

EMBO Molecular Medicine, 2020
Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8+ cytotoxic T lymphocyte (CTL ...
Zhenzhen Fan, Yahui Tian, Zhipeng Chen, Lu Liu, Qian Zhou, Jingjing He, James Coleman, Changjiang Dong, Nan Li, Junqi Huang, Chenqi Xu, Zhimin Zhang, Song Gao, Penghui Zhou, Ke Ding, Liang Chen   +15 more
doaj   +1 more source

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy [PDF]

Clinical Cancer Research, 2014
Abstract Purpose: Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies. Identifying factors predicting clinical response could guide patient selection and therapeutic optimization. Experimental Design: Patients (N = 41) with melanoma, non–small cell lung carcinoma (NSCLC ...
Janis M, Taube, Alison, Klein, Julie R, Brahmer, Haiying, Xu, Xiaoyu, Pan, Jung H, Kim, Lieping, Chen, Drew M, Pardoll, Suzanne L, Topalian, Robert A, Anders   +9 more
openaire   +2 more sources

Novel nonalloyed thermally stable Pd/Sn and Pd/Sn/Au ohmic contacts for the fabrication of GaAs MESFETs [PDF]

, 2001
GaAs metal-semiconductor field-effect transistors (MESFETs) have been fabricated utilizing thermally stable Pd/Sn and Pd/Sn/Au ohmic contacts for the first time. MESFETs with Pd/Ge ohmic contacts are fabricated for comparison.
McNally, Patrick J., Islam, Md. Shafiqul
core   +1 more source

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy

Molecules, 2021
Blockade of the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction is currently the focus in the field of cancer immunotherapy, and so far, several monoclonal antibodies (mAbs) have achieved encouraging outcomes in cancer ...
Hongbo Zhang, Yu Xia, Chunqiu Yu, Huijie Du, Jinchang Liu, Hui Li, Shihui Huang, Qihua Zhu, Yungen Xu, Yi Zou   +9 more
doaj   +1 more source

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma

Zhongliu Fangzhi Yanjiu, 2020
Malignant melanoma is the most serious type of skin cancer with a high recurrence rate and death rate. Surgery still is the cornerstone of treatment for patients with stage Ⅱ and Ⅲ melanoma.
ZOU Hanhui, Li Tao
doaj   +1 more source